Biochemical Behaviours of Salmeterol/Fluticasone Propionate in Treating Asthma and Chronic Obstructive Pulmonary Diseases (COPD) by Hilla Mills, Ronald Acquah, Nova Tang, Luke Cheung, Susanne Klenk, Ronald Glassen, Magali Pirson, Alain Albert, Duong Trinh Hoang, Thang Nguyen Van

“…Specific doses are prescribed accurately paying attention to factors like age, gender, race, and genetic makeup since these affect drug metabolisms. Generally, the ICS work by translocating glucocorticoid receptors to the nucleus from the cytosol. …”
Get full text

Novel inhibitors of the (VIBVN) NAT protein identified through pharmacophore modeling by Wei Wei, Xionghao Li, Ning Hou, Aowei Xie, Huicong Liang, Ting Gao, Xiaoli Jing, Liqin Li, Jiejie Hao, Ximing Xu

“…Abstract Arylamine N-acetyltransferases (NATs, E.C. 2.3.1.5) constitute a family of phase II drug metabolizing enzymes. These enzymes catalyze the transfer of acetyl groups from acetyl-CoA to a variety of substrates including arylamines, arylhydrazines, and N-hydroxyarylamines. …”
Get full text

Utility of Integrated Analysis of Pharmacogenomics and Pharmacometabolomics in Early Phase Clinical Trial: A Case Study of a New Molecular Entity by Jaeseong Oh, Sojeong Yi, Namyi Gu, Dongseong Shin, Kyung-Sang Yu, Seo Hyun Yoon, Joo-Youn Cho, In-Jin Jang

“…The pharmacogenomics screening was performed from whole blood samples using the Affymetrix DMET (Drug-Metabolizing Enzymes and Transporters) Plus microarray, and confirmation of genetic variants was performed using real-time polymerase chain reaction. …”
Get full text

Establishing a physiologically based pharmacokinetic framework for aldehyde oxidase and dual aldehyde oxidase‐CYP substrates by Nihan Izat, Jayaprakasam Bolleddula, Pasquale Carione, Leticia Huertas Valentin, Robert S. Jones, Priyanka Kulkarni, Darren Moss, Vincent C. Peterkin, Dan‐Dan Tian, Andrea Treyer, Karthik Venkatakrishnan, Michael A. Zientek, Jill Barber, J. Brian Houston, Aleksandra Galetin, Daniel Scotcher

“…Abstract Aldehyde oxidase (AO) contributes to the clearance of many approved and investigational small molecule drugs, which are often dual substrates of AO and drug‐metabolizing enzymes such as cytochrome P450s (CYPs). …”
Get full text

Continuous Consumption of Reused Palm Oil Induced Hepatic Injury, Depletion of Glutathione Stores, and Modulation of Cytochrome P450 Profiles in Mice by Waranya Chatuphonprasert, Yollada Sriset, Kanokwan Jarukamjorn

“…The expression profiles of drug-metabolizing CYPs were significantly modulated; Cyp2c29, Cyp3a11 , and Cyp3a13 were suppressed by both fresh and reused oil, while only the reused oil elevated Cyp2e1 . …”
Get full text

Comparison of clinical and pharmacodynamic features of proton pump inhibitors efficacy in gastroesophageal reflux disease by O. A. Storonova, A. S. Trukhmanov

“…Intensity of acid-suppressive action of PPI depends on drug metabolic pathways and genetically determined features of cytochrome P450 system. …”
Get full text

In vitro study of size-dependent inhibition of human cytochrome P450 (P450) P450-1A2, P450-2A6, P450-2B6, P450-2C8, P450-2E1, P450-2J2, and P450-3A5 by zinc oxide nanoparticles (Zn... by Lamia Chowdhury, Yuh Fen Pung, Swee Yong Pung, Chin Eng Ong, Cin Kong, Yan Pan

“…In conclusion, the interactions between ZnONP products and co-administered drugs metabolized by these inhibited P450-isozymes should be further investigated using in vivo models. …”
Get full text